COVINGTON, Ky. — CTI Clinical Trial and Consulting Services, a multi-national, privately held, full-service contract research organization, has announced the promotion of John Adams, PharmD, RAC to senior director, regulatory and scientific affairs.
Adams joined CTI’s regulatory and scientific affairs group in 2017 after years of working with the CTI team from the sponsor side. He brought with him expertise gained from work in both clinical pharmacy practice and in the pharmaceutical and biotechnology industries.
“John is a true perfectionist and provides thoughtful and innovative strategic regulatory approaches to our clients as well as serves as a mentor to the CTI team, ” said Lynn Fallon, president. “His methodical approach and clear understanding of drug development and what it takes to get a product approved results in the creation of high quality deliverables for our clients. John has quickly become the ‘go to’ person in cell and gene therapy development and is an active participant in the Alliance for Regenerative Medicine Organization. ”
In his new role, Adams will continue to collaborate on strategic regulatory projects; development of NDA’s and BLA’s, collaborate with the CTI business development team, and act as a mentor contributing to the continued growth and development of the regulatory and scientific affairs team.